Outcomes of Laparoscopic Total Gastrectomy Combined With Spleen-Preserving Hilar Lymphadenectomy for Locally Advanced Proximal Gastric Cancer

Key Points Question What are the 3-year outcomes after laparoscopic total gastrectomy combined with spleen-preserving splenic hilar lymphadenectomy for patients with locally advanced proximal gastric cancer? Findings In this nonrandomized clinical trial of 251 patients with clinically staged, locally advanced upper-third gastric cancer, the 3-year overall survival was 79.1%. The 3-year therapeutic value index of lymph node 10 dissection was 4.5, exceeding the index for the partial D2 lymph node group. Meaning The findings of this study suggest the utility of laparoscopic total gastrectomy combined with spleen-preserving splenic hilar lymphadenectomy for clinically staged, locally advanced upper-third gastric cancer.

[1]  D. Park,et al.  Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2018 (5th edition) , 2020, Gastric Cancer.

[3]  J. Ji,et al.  Safety and feasibility of laparoscopic spleen-preserving No. 10 lymph node dissection for locally advanced upper third gastric cancer: a prospective, multicenter clinical trial , 2019, Surgical Endoscopy.

[4]  D. Park,et al.  Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT). , 2019, Annals of surgery.

[5]  J. Ji,et al.  Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. , 2019, JAMA.

[6]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[7]  H. Xi,et al.  Randomized controlled trial comparing short‐term outcomes of laparoscopic and open spleen‐preserving splenic hilar lymphadenectomy for advanced proximal gastric cancer: An interim report , 2018, Journal of surgical oncology.

[8]  D. Graham,et al.  Changing Trends in Stomach Cancer Throughout the World , 2017, Current Gastroenterology Reports.

[9]  T. Yoshikawa,et al.  Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma , 2017, Annals of surgery.

[10]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2014 (ver. 4) , 2016, Gastric Cancer.

[11]  Zongguang Zhou,et al.  Changes of Esophagogastric Junctional Adenocarcinoma and Gastroesophageal Reflux Disease Among Surgical Patients During 1988–2012 , 2015, Annals of surgery.

[12]  D. Shin,et al.  Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[13]  Y. Bang,et al.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.

[14]  D. Ichikawa,et al.  Survival benefits from splenic hilar lymph node dissection by splenectomy in gastric cancer patients: relative comparison of the benefits in subgroups of patients , 2011, Gastric Cancer.

[15]  S. Ohno,et al.  Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer. , 2009, Anticancer research.

[16]  K. Yamashita,et al.  Laparoscopy-assisted pancreas- and spleen-preserving total gastrectomy for gastric cancer as compared with open total gastrectomy , 2009, Surgical Endoscopy.

[17]  M. Choi,et al.  Clinical Significance of Splenic Hilar Lymph Node Metastasis in Proximal Gastric Cancer , 2009, Annals of Surgical Oncology.

[18]  S. Choi,et al.  Laparoscopic spleen-preserving splenic hilar lymph node dissection during total gastrectomy for gastric cancer. , 2008, Journal of the American College of Surgeons.

[19]  H. Chung,et al.  Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer , 2006, The British journal of surgery.

[20]  M. Ikeguchi,et al.  Lymph Node Metastasis at the Splenic Hilum in Proximal Gastric Cancer , 2004, The American surgeon.

[21]  A. Csendes,et al.  A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. , 2002, Surgery.

[22]  M. Sasako,et al.  New method to evaluate the therapeutic value of lymph node dissection for gastric cancer , 1995, The British journal of surgery.

[23]  D. Park,et al.  Long-term outcome of endoscopic submucosal dissection is comparable to that of surgery for early gastric cancer: a propensity-matched analysis , 2017, Gastric Cancer.

[24]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2010 (ver. 3) , 2011, Gastric Cancer.